MK-677 TikTok claims: what the science actually supports

What did @bcm_lifestyle actually say?

Ben, a self-identified licensed pharmacist, walked his 747K viewers through MK-677 (ibutamoren), framing it as a drug that "wasn't meant to be in fitness" but landed there anyway. He credited it with boosting growth hormone and IGF-1 without raising cortisol, then listed a range of claimed benefits: muscle mass, bone density, sleep quality, skin health, fat burning, and appetite stimulation. He was upfront that it's not FDA-approved, flagged it as banned in sport, ran through a legitimate list of side effects including reduced insulin sensitivity, and stopped short of recommending a dose. He closed by telling viewers to find a "reputable source" and get bloodwork done.

That's a more honest framing than most fitness TikTok. But honest framing and scientifically precise framing are not the same thing, and there are a few places where the two diverge here.

Does the science back this up?

The core pharmacology is correct. MK-677 is a ghrelin receptor agonist, not a peptide, that stimulates pituitary release of growth hormone and downstream IGF-1. The cortisol claim also holds up, at least in the short-term literature. But many of the fitness benefits are oversold relative to what controlled trials actually show.

A landmark study by Nass et al. (2008, Annals of Internal Medicine) found that MK-677 increased lean body mass and improved some functional measures in older adults, but also worsened insulin resistance and caused fluid retention. Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) showed sustained GH and IGF-1 elevation over two years in elderly subjects, with the cortisol-sparing effect holding. However, the trial populations were elderly patients with GH deficiency, not healthy people chasing muscle gains. Extrapolating those results to a young, training population is a stretch the evidence doesn't fully support. Sleep improvement is one of the more credible claims: Copinschi et al. (1997, Sleep) documented increased slow-wave sleep duration with ibutamoren in healthy young adults. Fat burning is where the evidence gets thin fast.

What did they get wrong (or right)?

Ben deserves credit for getting the side effect profile right and for refusing to give dosing information. That's a higher standard than most fitness creators hold themselves to. The cortisol claim is also accurate based on available data.

Where things slip: calling it a drug that offers "fat burning properties" is misleading. The Nass 2008 trial actually showed an increase in fat mass in some participants, and the mechanism for fat loss in a healthy person on MK-677 is not well established. The appetite stimulation Ben mentions is real and significant, but framing it as a benefit alongside fat burning without noting the contradiction is a gap worth flagging.

His suggestion to find a "reputable source" for an unapproved compound is also complicated. There is no regulated supply chain for MK-677 sold for human use outside of a licensed compounding pharmacy or clinical trial. Telling viewers to source it carefully implies that careful sourcing solves the regulatory and safety problem. It does not. Purity testing data on gray-market MK-677 is inconsistent at best.

What should you actually know?

MK-677 is not a peptide. It is a small-molecule ghrelin mimetic, which matters because its pharmacological profile differs from injectable secretagogues like ipamorelin or CJC-1295. It is orally bioavailable, which is why it is popular, but oral bioavailability also means it stays in your system longer and produces sustained GH elevation that may not be physiologically appropriate outside a clinical context.

The insulin sensitivity issue Ben flags is not a minor footnote. Nass et al. (2008) found clinically meaningful increases in fasting blood glucose in older adults. In a young person with any predisposition to metabolic dysfunction, that signal matters. If you are considering any GH secretagogue, bloodwork before and during use is not optional advice, it is the minimum reasonable standard. WADA added ibutamoren to the prohibited list under S2 (peptide hormones, growth factors, related substances), so any athlete subject to testing faces real consequences regardless of how careful their sourcing is.